Your Advocates Ltd. LLP increased its holdings in shares of Humana Inc. (NYSE:HUM – Free Report) by 81.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 100 shares of the insurance provider’s stock after buying an additional 45 shares during the period. Your Advocates Ltd. LLP’s holdings in Humana were worth $32,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also modified their holdings of the business. Pzena Investment Management LLC grew its holdings in Humana by 538.7% during the second quarter. Pzena Investment Management LLC now owns 2,318,347 shares of the insurance provider’s stock valued at $866,250,000 after purchasing an additional 1,955,375 shares during the period. Davis Selected Advisers grew its holdings in Humana by 16.1% during the second quarter. Davis Selected Advisers now owns 2,311,362 shares of the insurance provider’s stock valued at $863,640,000 after purchasing an additional 321,233 shares during the period. Marshall Wace LLP grew its holdings in Humana by 118.9% during the second quarter. Marshall Wace LLP now owns 1,425,302 shares of the insurance provider’s stock valued at $532,564,000 after purchasing an additional 774,085 shares during the period. Legal & General Group Plc grew its holdings in Humana by 2.1% during the second quarter. Legal & General Group Plc now owns 1,183,985 shares of the insurance provider’s stock valued at $442,396,000 after purchasing an additional 24,842 shares during the period. Finally, Ontario Teachers Pension Plan Board grew its holdings in Humana by 11,647.2% during the first quarter. Ontario Teachers Pension Plan Board now owns 1,059,478 shares of the insurance provider’s stock valued at $367,342,000 after purchasing an additional 1,050,459 shares during the period. 92.38% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
HUM has been the subject of several research analyst reports. Bank of America cut shares of Humana from a “neutral” rating to an “underperform” rating and reduced their price target for the company from $376.00 to $247.00 in a report on Wednesday, October 2nd. Oppenheimer reduced their price target on shares of Humana from $400.00 to $280.00 and set an “outperform” rating for the company in a report on Thursday, October 3rd. Piper Sandler cut shares of Humana from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $392.00 to $274.00 in a report on Thursday, October 3rd. Sanford C. Bernstein upgraded shares of Humana from a “market perform” rating to an “outperform” rating and set a $308.00 price target for the company in a report on Tuesday, October 8th. Finally, Jefferies Financial Group cut shares of Humana from a “buy” rating to a “hold” rating and reduced their price target for the company from $519.00 to $253.00 in a report on Monday, October 7th. One research analyst has rated the stock with a sell rating, nineteen have issued a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $315.33.
Humana Stock Performance
NYSE HUM opened at $252.50 on Wednesday. The company has a current ratio of 1.66, a quick ratio of 1.66 and a debt-to-equity ratio of 0.70. The firm’s fifty day moving average price is $302.69 and its two-hundred day moving average price is $335.58. Humana Inc. has a 1 year low of $213.31 and a 1 year high of $527.18. The firm has a market capitalization of $30.43 billion, a P/E ratio of 16.05, a price-to-earnings-growth ratio of 2.04 and a beta of 0.50.
Humana (NYSE:HUM – Get Free Report) last issued its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share for the quarter, beating the consensus estimate of $5.89 by $1.07. The company had revenue of $29.54 billion for the quarter, compared to analyst estimates of $28.52 billion. Humana had a net margin of 1.53% and a return on equity of 16.12%. The company’s revenue was up 10.4% on a year-over-year basis. During the same period in the prior year, the firm earned $8.94 earnings per share. As a group, research analysts anticipate that Humana Inc. will post 16.06 EPS for the current year.
Humana Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be given a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.40%. The ex-dividend date is Tuesday, December 31st. Humana’s payout ratio is presently 22.04%.
About Humana
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
See Also
- Five stocks we like better than Humana
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
- How to Calculate Stock Profit
- 3 ETFs With Low Fees and Market-Beating Returns
- What is a support level?
- Inflation Threats Make Yield Curve ETFs a Top Trade
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.